CAS |
30045-16-0 |
Chinese Name |
脱氢紫堇碱 |
English Name |
Dehydrocorydalin |
Synonyms |
Dehydrocorydalin;13-Methylpalmatine |
Molecular Formula |
C22H24NO4 |
Molecular Weight |
366.43 |
Solubility |
Soluble in DMSO ≥5mg/mL(Need ultrasonic) |
Purity |
HPLC≥98% |
Appearance |
Light yellow to yellow Solid |
Storage |
Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year |
MDL |
MFCD00887635 |
SMILES |
CC1=C(C=CC(OC)=C2OC)C2=C[N+]3=C1C4=CC(OC)=C(OC)C=C4CC3 |
InChIKey |
RFKQJTRWODZPHF-UHFFFAOYSA-N |
InChI |
InChI=1S/C22H24NO4/c1-13-15-6-7-18(24-2)22(27-5)17(15)12-23-9-8-14-10-19(25-3)20(26-4)11-16(14)21(13)23/h6-7,10-12H,8-9H2,1-5H3/q+1 |
PubChem CID |
34781 |
Target Point |
Bcl-2 Family; Caspase; PARP; p38 MAPK; Parasite; Autophagy |
Passage |
MAPK |
Background |
It is an alkaloid in the traditional Chinese medicine Corydalis yanhusuo. Regulates Bax, Bcl-2 protein expression; activates caspase-7, caspase-8, and inactivates PARP. |
Biological Activity |
Dehydrocorydaline (13-Methylpalmatine) 是从中药延胡索 Corydalis yanhusuo 中分离得到的一种生物碱。Dehydrocorydaline 调节 Bax,Bcl-2 蛋白表达;激活 caspase-7,caspase-8,并使 PARP 失活。[1-2] |
In Vitro |
脱氢二氢萘(0-200μM)处理以剂量依赖性方式显着抑制MCF-7细胞的生长。在200μMDehydrocorydaline[1] 24小时后,细胞存活率降低约40%。脱氢肾上腺素(0-200μM)剂量依赖性地增加Bax蛋白表达并降低Bcl-2蛋白表达[1]。 Dehydrocorydaline(0-200μM)诱导caspase-7,-8的激活和PARP的裂解而不影响caspase-9 [1]。 |
In Vivo |
脱氢去甲肾上腺素表现出低急性毒性,口服给药后小鼠的LD50约为277.5±19.0mg / kg体重,腹腔注射为21.1±1.4mg / kg [2]。 |
Data Literature Source |
[1]. Xu Z,et al. Dehydrocorydaline inhibits breast cancer cells proliferation by inducing apoptosis in MCF-7 cells. Am J Chin Med. 2012;40(1):177-85. [2]. Yin ZY,et al. Antinociceptive effects of dehydrocorydaline in mouse models of inflammatory pain involve the opioid receptor and inflammatory cytokines. Sci Rep. 2016 Jun 7;6:27129 |
Unit |
Bottle |
Specification |
5mg 10mg 20mg |